Novel treatments, such as FOXM1 inhibitor co-treatment with platinum, are potential therapeutic strategies to reduce the necessary dosage of cisplatin and enhance the therapeutic efficacy in treating ovarian cancer. The gene discussed is FOXM1; the disease is ovarian carcinoma.